Serum drug level-related sodium valproate-induced hair loss
Open Access
- 1 January 2013
- journal article
- case report
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 45 (2) , 187-8
Abstract
Sodium valproate is a well-established treatment in epilepsy and mood disorders. Its utility is compromised by its adverse effects such as tremor, weight gain, hair loss, and liver dysfunction. Hair loss may occur when drug is used in higher dose. Drug-induced hair loss is diffused and non-scarring, which is reversible upon withdrawal. But there are no case reports showing relation between serum levels of valproate and occurrence of hair loss. So we took interest in reporting this case report.Keywords
This publication has 10 references indexed in Scilit:
- Adverse cutaneous reactions to psychopharmaceuticals.2010
- Diffuse hair loss in an adult female: Approach to diagnosis and managementIndian Journal of Dermatology, Venereology and Leprology, 2009
- Hair Loss in WomenNew England Journal of Medicine, 2007
- Valproic Acid–induced Hair‐texture Changes in a White WomanEpilepsia, 2007
- Telogen Effluvium Caused by Magnesium Valproate and LamotrigineActa Dermato-Venereologica, 2005
- Telogen effluviumClinical and Experimental Dermatology, 2002
- Hair Loss in PsychopharmacologyAnnals of Clinical Psychiatry, 2000
- Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescentsJournal of Adolescent Health, 1998
- Drug-Induced Hair Loss and Hair GrowthDrug Safety, 1994
- Alopecia and mood stabilizers: Two case reportsEuropean Archives of Psychiatry and Clinical Neuroscience, 1992